NO20074453L - Bruk av det ikke-opiatiske, smertestillende middelet flupirtin for behandling av overaktiv blaere og assosierte sykdommer, inkludert urgeinkontinens, problemer med urinstrommen som folge av prostata-hyperplasi og irritabelt tarmsyndrom - Google Patents

Bruk av det ikke-opiatiske, smertestillende middelet flupirtin for behandling av overaktiv blaere og assosierte sykdommer, inkludert urgeinkontinens, problemer med urinstrommen som folge av prostata-hyperplasi og irritabelt tarmsyndrom

Info

Publication number
NO20074453L
NO20074453L NO20074453A NO20074453A NO20074453L NO 20074453 L NO20074453 L NO 20074453L NO 20074453 A NO20074453 A NO 20074453A NO 20074453 A NO20074453 A NO 20074453A NO 20074453 L NO20074453 L NO 20074453L
Authority
NO
Norway
Prior art keywords
result
bowel syndrome
irritable bowel
prostate hyperplasia
painkiller
Prior art date
Application number
NO20074453A
Other languages
English (en)
Inventor
Hildegard Kuss
Chris Rundfeldt
Regina Draheim
Katrin Bernoester
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of NO20074453L publication Critical patent/NO20074453L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Foreliggende oppfinnelse omhandler forhindringen, reverseringen og den medisinske behandling av dysfunksjon i de nedre urinveiene inkludert blæreinstabilitet og andre relaterte sykdommer som beskrevet under inkludert problemer med urinstrøm, urgency og inkontinens som et resultat av prostata hyperplasi (BPH) og forhindringen, reverseringen og den medisinske behandling av irritabel tarm syndrom (IBS) med spesielt fokus på den diarédominerte og blandet diaré-konstipasjon type IBS, både hos mennesker og dyr.
NO20074453A 2005-01-31 2007-08-31 Bruk av det ikke-opiatiske, smertestillende middelet flupirtin for behandling av overaktiv blaere og assosierte sykdommer, inkludert urgeinkontinens, problemer med urinstrommen som folge av prostata-hyperplasi og irritabelt tarmsyndrom NO20074453L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05001967A EP1688141A1 (en) 2005-01-31 2005-01-31 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PCT/EP2006/000814 WO2006079559A2 (en) 2005-01-31 2006-01-31 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
NO20074453L true NO20074453L (no) 2007-10-18

Family

ID=34933533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074453A NO20074453L (no) 2005-01-31 2007-08-31 Bruk av det ikke-opiatiske, smertestillende middelet flupirtin for behandling av overaktiv blaere og assosierte sykdommer, inkludert urgeinkontinens, problemer med urinstrommen som folge av prostata-hyperplasi og irritabelt tarmsyndrom

Country Status (14)

Country Link
US (1) US7309713B2 (no)
EP (2) EP1688141A1 (no)
KR (1) KR20070102726A (no)
CN (1) CN101132793A (no)
AR (1) AR055723A1 (no)
AU (1) AU2006208618A1 (no)
BR (1) BRPI0606897A2 (no)
CA (1) CA2596619A1 (no)
IL (1) IL183557A0 (no)
MX (1) MX2007009187A (no)
NO (1) NO20074453L (no)
RU (1) RU2007132725A (no)
TW (1) TW200637548A (no)
WO (1) WO2006079559A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
PL3409274T3 (pl) * 2008-12-22 2020-06-01 Novartis Ag Schemat dawkowania dla agonisty receptora s1p
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN109053562B (zh) * 2018-07-20 2022-05-27 四川青木制药有限公司 一种制备a晶型高堆密度的马来酸氟吡汀的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670523A1 (de) * 1966-05-12 1970-12-03 Degussa Verfahren zur Herstellung neuer substituierter Aminopyridine
DE1670255A1 (de) * 1967-08-02 1971-01-28 Basf Ag Verfahren zur Herstellung von 2-Aryl-3-amino-indazolen
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
IN172468B (no) * 1990-07-14 1993-08-14 Asta Medica Ag
GB9220570D0 (en) 1991-10-21 1992-11-11 Ici Plc Therapeutic agent
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
DE4236752A1 (de) 1992-10-30 1994-05-05 Asta Medica Ag Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit
DE4319649A1 (de) 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
AU1353901A (en) 1999-12-01 2001-06-12 Duke University Method of treating batten disease
US6412554B1 (en) * 2000-03-14 2002-07-02 Weatherford/Lamb, Inc. Wellbore circulation system
MXPA03000032A (es) 2000-06-29 2003-08-19 Neurosearch As Uso de derivados de oxindol 3-sustituidos como moduladores de los canales de potasio kcnq.
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function

Also Published As

Publication number Publication date
CA2596619A1 (en) 2006-08-03
AU2006208618A1 (en) 2006-08-03
KR20070102726A (ko) 2007-10-19
US20060173052A1 (en) 2006-08-03
EP1688141A1 (en) 2006-08-09
WO2006079559A2 (en) 2006-08-03
WO2006079559A3 (en) 2006-11-02
US7309713B2 (en) 2007-12-18
CN101132793A (zh) 2008-02-27
AR055723A1 (es) 2007-09-05
BRPI0606897A2 (pt) 2009-07-21
TW200637548A (en) 2006-11-01
RU2007132725A (ru) 2009-03-10
EP1843765A2 (en) 2007-10-17
IL183557A0 (en) 2007-10-31
MX2007009187A (es) 2007-09-21

Similar Documents

Publication Publication Date Title
NO20074453L (no) Bruk av det ikke-opiatiske, smertestillende middelet flupirtin for behandling av overaktiv blaere og assosierte sykdommer, inkludert urgeinkontinens, problemer med urinstrommen som folge av prostata-hyperplasi og irritabelt tarmsyndrom
Chapple Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
Schwinn et al. α1‐Adrenoceptor subtypes and lower urinary tract symptoms
Fitzpatrick et al. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia
Chapple et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with α-blockers
Donatucci et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1‐year, open‐label extension study
Kirby A randomized, double‐blind crossover study of tamsulosin and controlled‐release doxazosin in patients with benign prostatic hyperplasia
WO2006018743A3 (en) Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder
Roehrborn et al. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6‐month, randomized, double‐blind study comparing finasteride plus tadalafil with finasteride plus placebo
Nickel et al. The beneficial effect of alfuzosin 10 mg once daily in ‘real‐life’practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation
Hussan et al. Anti‐inflammatory property of Plantago major leaf extract reduces the inflammatory reaction in experimental acetaminophen‐induced liver injury
Kamal et al. Impact of posterior urethral valves on pediatric renal transplantation: A single‐center comparative study of 297 cases
De Reijke et al. Comparative efficacy of two α1‐adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement
Yang et al. A current perspective on post-micturition dribble in males
Joo et al. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia
Giuliano et al. A placebo‐controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder
Tsai et al. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia
Devarajan et al. Combined transurethral prostatectomy and inguinal hernia repair: a retrospective audit and literature review
Araki et al. Comparison of 7 α1-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A short-term crossover study
Seki et al. Non‐inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel‐group study
RU2011110517A (ru) Новое терапевтическое применение дротаверина
Shinosaki et al. Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis
Siddique et al. Efficacy and safety of combine alfuzosin and finasteride in the treatment of symptomatic benign prostatic hyperplasia: a quasi-experimental study
Araki et al. Early effect of dutasteride added to alpha‐1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia
Jain et al. Prevalence of lower urinary tract symptoms in patients undergoing inguinal hernia repair